Progress and challenges in the prevention and control of nonalcoholic fatty liver disease

Jingjing Cai; Xiao-Jing Zhang; Hongliang Li

doi:10.1002/med.21515

Progress and challenges in the prevention and control of nonalcoholic fatty liver disease

Med Res Rev. 2019 Jan;39(1):328-348. doi: 10.1002/med.21515. Epub 2018 May 30.

Authors

Jingjing Cai^{1

2

3}, Xiao-Jing Zhang^{1

3}, Hongliang Li^{1

3

4}

Affiliations

¹ Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
² Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, China.
³ Institute of Model Animal of Wuhan University, Wuhan, China.
⁴ Basic Medical School, Wuhan University, Wuhan, China.

PMID: 29846945
DOI: 10.1002/med.21515

Abstract

Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide. Individuals with NAFLD have a high frequency of developing progressive liver disease and metabolism-related comorbidities, which result from of a lack of awareness and poor surveillance of the disease and a paucity of approved and effective therapies. Managing the complications of NAFLD has already begun to place a tremendous burden on health-care systems. Although efforts to identify effective therapies are underway, the lack of validated preclinical NAFLD models that represent the biology and outcomes of human disease remains a major barrier. This review summarizes the characteristics and prevalence of the disease and the status of our understanding of its mechanisms and potential therapeutic targets.

Keywords: animal model; awareness; epidemiology; molecular target; nonalcoholic fatty liver disease (NAFLD).

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Disease Models, Animal
Health Knowledge, Attitudes, Practice
Health Personnel
Humans
Molecular Targeted Therapy
Non-alcoholic Fatty Liver Disease / epidemiology
Non-alcoholic Fatty Liver Disease / pathology
Non-alcoholic Fatty Liver Disease / prevention & control*
Non-alcoholic Fatty Liver Disease / therapy
Population Surveillance